利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.036 秒)

    4-Aryl piperidines
    1.
    发明申请
    4-Aryl piperidines 审中-公开
    4-芳基哌啶

    公开(公告)号：US20050154020A1

    公开(公告)日：2005-07-14

    申请号：US10757962

    申请日：2004-01-14

    申请人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  John Deleon ,  Yu Jiang ,  Kai Lu

    发明人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  John Deleon ,  Yu Jiang ,  Kai Lu

    IPC分类号： C07D211/26 ,  A61K31/4545 ,  C07D41/14

    CPC分类号： C07D211/26

    摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

    4-aryl piperidines
    2.
    发明申请
    4-aryl piperidines 审中-公开
    4-芳基哌啶

    公开(公告)号：US20050154022A1

    公开(公告)日：2005-07-14

    申请号：US11034611

    申请日：2005-01-13

    申请人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  John DeLeon ,  Yu Jiang ,  Kai Lu

    发明人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  John DeLeon ,  Yu Jiang ,  Kai Lu

    IPC分类号： C07D211/26 ,  C07D401/12 ,  A61K31/4545 ,  C07D41/14

    CPC分类号： C07D401/12 ,  C07D211/26

    摘要： This invention is directed to 4-aryl piperidines and related heterocyclic compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的4-芳基哌啶和相关的杂环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

    Substituted alkyl amido piperidines
    4.
    发明申请
    Substituted alkyl amido piperidines 失效
    取代的烷基酰氨基哌啶

    公开(公告)号：US20060084649A9

    公开(公告)日：2006-04-20

    申请号：US10753057

    申请日：2004-01-06

    申请人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu

    发明人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu

    IPC分类号： A61K31/53 ,  A61K31/506 ,  A61K31/497 ,  C07D43/04

    CPC分类号： C07D211/26 ,  C07D211/28 ,  C07D211/90 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/10 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04

    摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

    Spirocvclic piperidines as mch1 antagonists and uses thereof
    5.
    发明申请
    Spirocvclic piperidines as mch1 antagonists and uses thereof 失效
    作为mch1拮抗剂的西吡唑哌啶及其用途

    公开(公告)号：US20060173027A1

    公开(公告)日：2006-08-03

    申请号：US10518939

    申请日：2003-07-03

    申请人： Mohammad Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel ,  Kim Andersen

    发明人： Mohammad Marzabadi ,  Yu Jiang ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel ,  Kim Andersen

    IPC分类号： A61K31/4747

    CPC分类号： C07D221/20 ,  C07D401/06 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D491/10

    摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。

    SUBSTITUTED ALKYL AMIDO PIPERIDINES
    7.
    发明申请
    SUBSTITUTED ALKYL AMIDO PIPERIDINES 失效
    取代的烷基氨基哌啶

    公开(公告)号：US20060041139A9

    公开(公告)日：2006-02-23

    申请号：US10345063

    申请日：2003-01-14

    申请人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu

    发明人： Mohammad Marzabadi ,  John Wetzel ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu

    IPC分类号： C07D41/02 ,  C07D211/80

    CPC分类号： C07D211/26 ,  C07D211/28 ,  C07D211/90 ,  C07D231/12 ,  C07D233/56 ,  C07D249/08 ,  C07D401/04 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/06 ,  C07D405/12 ,  C07D409/06 ,  C07D409/10 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/06 ,  C07D417/10 ,  C07D471/04 ,  C07D495/04

    摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的有效治疗受试者的抑郁症和/或焦虑症的本发明化合物。

    Amino substituted aryloxybenzylpiperidine derivatives
    8.
    发明申请
    Amino substituted aryloxybenzylpiperidine derivatives 审中-公开
    氨基取代的芳氧基苄基哌啶衍生物

    公开(公告)号：US20060079522A1

    公开(公告)日：2006-04-13

    申请号：US10962099

    申请日：2004-10-08

    申请人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

    发明人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

    IPC分类号： A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  C07D403/14 ,  C07D413/14

    CPC分类号： C07D211/26 ,  C07D401/12 ,  C07D403/12

    摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

    摘要翻译： 本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括给予受试者一定量的本发明化合物。

    Secondary amino anilinic piperidines as mch1 antagonists and uses thereof
    9.
    发明申请
    Secondary amino anilinic piperidines as mch1 antagonists and uses thereof 失效
    仲氨基苯胺哌啶类作为mch1拮抗剂及其应用

    公开(公告)号：US20050245743A1

    公开(公告)日：2005-11-03

    申请号：US10518675

    申请日：2003-07-03

    申请人： Mohammad Marzabadi ,  Jiang Yu ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel

    发明人： Mohammad Marzabadi ,  Jiang Yu ,  Kai Lu ,  Chien-An Chen ,  John De Leon ,  John Wetzel

    IPC分类号： A61K31/44 ,  A61K31/451 ,  A61K31/4545 ,  A61K31/506 ,  A61P3/04 ,  A61P13/02 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00 ,  C07D211/26 ,  C07D211/70 ,  C07D401/12 ,  C07D211/68 ,  C07D41/02 ,  C07D43/02

    CPC分类号： C07D211/26 ,  C07D401/12

    摘要： This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.

    摘要翻译： 本发明涉及作为黑色素浓缩激素-1（MCH1）受体的选择性拮抗剂的化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物与药学上可接受的载体组合。 本发明还提供减少受试者体重的方法，其包括向受试者施用一定量的有效减少受试者体重的本发明化合物。 本发明进一步提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用有效治疗受试者抑郁症和/或焦虑的量的本发明化合物。 本发明还提供了治疗患有尿失禁的受试者的方法。

    Amino substituted aryloxybenzylpiperidine derivatives
    10.
    发明申请
    Amino substituted aryloxybenzylpiperidine derivatives 失效
    氨基取代的芳氧基苄基哌啶衍生物

    公开(公告)号：US20060079524A1

    公开(公告)日：2006-04-13

    申请号：US11230849

    申请日：2005-09-20

    申请人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

    发明人： Mohammad Marzabadi ,  Chien-An Chen ,  Yu Jiang ,  Kai Lu ,  Kim Andersen

    IPC分类号： A61K31/5377 ,  A61K31/4545 ,  A61K31/496 ,  C07D413/14 ,  C07D403/14

    CPC分类号： C07D211/26 ,  C07D211/34 ,  C07D401/12 ,  C07D403/12

    摘要： This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

    摘要翻译： 本发明涉及作为MCH1受体的配体的氨基取代的芳氧基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。